Immunotherapy Study for HPV-Positive Head and Neck Cancer
Treatments studied
Part of Cancer clinical trials.
This trial compares two different immunotherapy approaches for people with HPV-positive oropharyngeal cancer who have completed initial treatment like surgery, radiation, or chemotherapy. The goal is to see which option works better to keep the cancer from coming back, and eligibility is determined by a special blood test that detects HPV DNA.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have or had a type of throat cancer called squamous cell carcinoma of the oropharynx that is HPV-positive.
- You have completed your initial treatment (surgery, radiation, or chemotherapy) at least 1 month ago.
- A blood test shows you have detectable levels of HPV DNA from your tumor, which means some cancer cells may still be present but not visible on scans.
- You are 18 years or older and in generally good health (able to perform daily activities without major limitations).
- You are willing to have a biopsy or provide a tissue sample to check for a protein called PD-L1.
- You do not have other active cancers or serious medical conditions that could interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding a checkpoint immunotherapy (tislelizumab) and a cancer pill (pamiparib) to radiation can better treat cancer that has come back in the head and neck. It’s for adults with previously treated, HPV-positive oropharynx tumors, usually without widespread spread.
This Phase 1 trial tests how well cemiplimab (an immune treatment) can work when combined with chemotherapy and an additional immunotherapy for certain head and neck cancers. It may help shrink the cancer and improve outcomes, while also checking safety and dosing.
This trial tests a combination of chemotherapy and an immunotherapy drug called Toripalimab before surgery for certain head and neck cancers. The goal is to see if this approach can reduce the extent of treatment needed while still being effective.
This trial tests two immunotherapy drugs (cemiplimab and fianlimab) combined with standard chemotherapy and radiation for people with advanced head and neck cancer that cannot be removed by surgery. The goal is to see if this combination can improve outcomes by helping the immune system attack the cancer.
This trial tests a custom treatment plan for people with advanced head and neck cancer that is not caused by HPV. It combines radiation and chemotherapy with a targeted drug called cetuximab, adjusted based on your tumor's characteristics.
This study tests adding a new immunotherapy drug (toripalimab) to standard chemo for HPV-positive throat cancer. It aims to see if this combination works better than chemo alone for patients whose cancer has spread to nodes but not to other parts of the body.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.